UK economy grows 0.1% in Q3
Below expectations of a 0.2% increase
HEAD-TO-HEAD: Axa Framlington Biotech vs Polar Capital Healthcare Opportunities
In this week’s Head-to-Head, Gavin Haynes, managing director at Whitechurch Securities, matches up two medical heavyweights – Axa Framlington Biotech and Polar Capital Healthcare Opportunities.
